메뉴 바로가기

본문으로 바로가기

Home / 제품소개 / 상세페이지

COVID-19 Ag + FLU A&B

Qualitative test for COVID-19 Ag + FLU A&B

The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens.


KEY FEATURES & BENEFITS

- 3 minutes | Fast result

- 2 steps | Easy to use

- Microfluidic Qualitative Immunoassay

- LIS connectivity (data management)

- COVID-19 Ag | 95.56 % & 99.66% Percent Agreement

- Influenza A | 100.00 % & 99.67 % Percent Agreement

- Influenza B | 97.50 % & 98.66 % Percent Agreement


  
Microfluidic Qualitative Immunoassay
FREND™ COVID-19 Ag + Flu A&B
The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens.




 

  Instructions for use
Accurate result in 3 minutes!


With just simple steps of operation, the FREND™ system​​ supports quick decision-making.

 






 

Performance evaluation
Clinical agreement study

[COVID-19 Ag]
The total of 338 clinical samples (45 positive and 293 negative) confirmed with RT-PCR were tested.
It shows 95.56% PPA (Positive Percent Agreement) and 99.66% NPA (Negative Percent Agreement) shown as below.



[Influenza A]
The total of 338 clinical samples (38 positive and 300 negative) confirmed with RT-PCR were tested.
It shows 100% PPA (Positive Percent Agreement) and 99.67% NPA (Negative Percent Agreement) shown as below.



[Influenza B]
The total of 338 clinical samples (40 positive and 298 negative) confirmed with RT-PCR were tested. 
It shows 97.50% PPA (Positive Percent Agreement) and 98.66% NPA (Negative Percent Agreement) shown as below.

 


 

Effective Data Management

Laboratory Information System Connectivity

In the event of a pandemic, the management of a vast amount of clinical result is important. However, many laboratories face the challenge in arranging the essential information effectively(1).

The FREND™ System which is LIS compatible provide following features:




Visit NanoEntek blog now!

Want to learn more about cell counting and cell therapy?

Visit to find out more!

blog-nanoentek.com


 

  • Cat. No.

    FRCGFL 020

  • Specimen

    Nasopharyngeal swab

  • Volume

    35 μL

  • Time to result

    Cartridge reaction : < 3 min

  • Package

    20 tests

  • COVID-19 Product line up Introduction Video

    COVID-19 Product line up Introduction Video

Related downloads Total 2

  • COVID-19_Ag+FLU_A&B_IFU_NanoEntek

    다운로드

  • COVID-19_Ag+FLU_A&B_Brochure_NanoEntek

    다운로드

ExTransfection™ Protocol Library

ExTransfection™ provides open protocols that make it easy for users to set up and run experiments. Its 24-well optimization method helps users to optimize transfection protocols easily and quickly.

ExTransfection™ also offers a pre-programmed optimization protocol that helps an easy and quick optimization of electrical parameters for both adherent and suspended cells.

Go to Library →

전체제품 - ALL PRODUCT

 Related product